Brief: Epigenomics: Blood Test Shows Promise In The Detection Of Liver Cancer
19/04/2018 05:40
April 19 (Reuters) - Epigenomics AG ECXn.DE :
* DGAP-NEWS: EPIGENOMICS AG: BLOOD TEST SHOWS PROMISE IN THE DETECTION OF LIVER CANCER
* RESULTS FROM TWO CLINICAL STUDIES DEMONSTRATE HIGH SENSITIVITY AND SPECIFICITY OF MSEPT9
BLOOD
TEST
Source text for Eikon: ID:nEQtp6gMa
Further company coverage: ECXn.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns